A Phase 2 Study to Assess the Efficacy and Safety of GS-1101 (CAL-101) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2017
At a glance
- Drugs Idelalisib (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 07 Jun 2016 Results of post-hoc analayis of this and other trials (n=1073) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 23 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Aug 2019.